Humana Inc. is set to acquire privately held Enclara Healthcare, a hospice pharmacy and benefit management providers, from Consonance Capital Partners and Enclara management. Enclara is a pharmacy solutions provider focused on simplifying care delivery in complex care populations to improve patient experience, quality and cost.
The Enclara acquisition provides Humana with the opportunity to extend its comprehensive care continuum strategy to cover the pharmacy-related needs associated with hospice care, simplify the mail order pharmacy experience, and advance its technology stack for in-home pharmacy through areas such as enhanced mobile medication management and improved electronic medical record connectivity.
Enclara serves over 450 hospice providers and 97,000 hospice patients per day through multiple, scalable models designed to fit unique customer needs.
The Enclara transaction, which includes acquisition of Enclara Pharmacia, GuidantRx and Avanti Health Care Services, is anticipated to close during the first half of 2020 and is subject to customary state and federal regulatory approvals as well as other customary closing conditions. Financial terms of the transaction were not disclosed. The transaction is expected to have an immaterial impact to earnings in 2020.
Centerview Partners LLC is acting as financial adviser to Humana. Crowell & Moring LLP is acting as legal adviser to Humana. Evercore Inc. is acting as financial adviser to Enclara and Consonance Capital Partners. Latham & Watkins LLP is acting as legal adviser to Enclara and Consonance Capital Partners.
